Company chosen to be a MAIN/Stage presenter on November 6
Chapel Hill, NC, November 1, 2013 – G1 Therapeutics, Inc. today announced that it has been selected as a MAIN/Stage presenter at the 2013 Southeast BIO Investor & Partnering Forum to be held November 6-7 at the Jefferson Hotel in Richmond, Virginia. Christy Shaffer, Ph.D., Executive Chair of G1’s Board of Directors, will present to the audience of potential investors and partners on the afternoon of November 6. Jay Strum, Ph.D., President of G1, will also be in attendance.
The annual conference sponsored by Southeast BIO (SEBIO), the regional nonprofit organization dedicated to fostering the growth of the Southeast’s life sciences industry, will showcase innovative drug therapies, advanced medical devices, diagnostics and other cutting-edge healthcare technologies from throughout the Southeast. MAIN/Stage presenting companies have generally completed at least one round of institutional financing and were chosen by a selection committee of regional and national venture capitalists based on criteria including technology, market potential and company management.
G1’s lead clinical candidate is a proprietary, potent and selective cyclin-dependent kinase (CDK) 4/6 inhibitor that has been evaluated in a number of pre-clinical studies for the potential treatment of chemotherapy-induced myelosuppression. In October 2013, the company raised $12.5 million in a Series A financing led by MedImmune Ventures that will enable it to advance its lead clinical candidate into clinical trials. Based on a recent pre-IND meeting with the U.S. Food & Drug Administration, the company expects to file its IND by summer 2014 and initiate clinical testing before the end of 2014.
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc. is a privately held pharmaceutical company based in Chapel Hill, NC that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications. These molecules are being developed for targeting specific proteins associated with cell proliferation and growth. Such therapies may be useful to protect the bone marrow and other organs, including the kidney and lung, from toxic insult. In October 2013, the company raised $12.5 million in a Series A financing led by MedImmune Ventures that will enable it to advance its lead clinical candidate into clinical trials for the potential treatment of chemotherapy-induced myelosuppression. Visitwww.g1therapeutics.com for more information.